GRAIL, Inc. (GRAL)
60.50
+1.91
(+3.26%)
USD |
NASDAQ |
Jun 11, 13:34
GRAIL Shareholders Equity (Quarterly) : 2.501B for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 2.501B |
| December 31, 2025 | 2.578B |
| September 30, 2025 | 2.240B |
| June 30, 2025 | 2.315B |
| March 31, 2025 | 2.414B |
| December 31, 2024 | 2.503B |
| September 30, 2024 | 2.588B |
| June 30, 2024 | 2.695B |
| March 31, 2024 | 3.739B |
| December 31, 2023 | 3.646B |
| September 30, 2023 | |
| June 30, 2023 |
| Date | Value |
|---|---|
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | 609.94M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 1.256B |
| Evommune, Inc. | 304.56M |
| Arrowhead Pharmaceuticals, Inc. | 613.98M |
| Oncolytics Biotech, Inc. | -5.13M |
| Sangamo Therapeutics, Inc. | -18.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.803B |
| Total Liabilities (Quarterly) | 302.79M |
| Debt to Equity Ratio | 0.0204 |
| Current Ratio | 11.74 |
| Net Debt Paydown Yield | 0.16% |